Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 5,501 Shares

Key Points

• Insider Barry Ticho sold 5,501 shares of Stoke Therapeutics at an average price of $19.87, reducing their holdings by 22.95%.
• Stoke Therapeutics reported a quarterly earnings per share of ($0.40), outperforming the estimate of ($0.57), with revenue of $13.82 million compared to the expected $31.51 million.
• Analysts are optimistic about Stoke Therapeutics, with a consensus rating of "Buy" and an average target price of $25.57 per share.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider owned 18,469 shares of the company's stock, valued at $366,979.03. This trade represents a 22.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Friday, August 1st, Barry Ticho sold 4,504 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.82, for a total transaction of $57,741.28.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded up $0.18 during trading on Wednesday, hitting $19.77. The company's stock had a trading volume of 1,307,730 shares, compared to its average volume of 810,410. The business has a 50 day moving average price of $14.42 and a two-hundred day moving average price of $10.83. The company has a market capitalization of $1.08 billion, a PE ratio of 23.26 and a beta of 1.14. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $20.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. As a group, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Toronto Dominion Bank acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $35,001,000. Corient Private Wealth LLC acquired a new position in Stoke Therapeutics during the second quarter worth approximately $7,489,000. RTW Investments LP increased its position in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after acquiring an additional 471,240 shares in the last quarter. Checkpoint Capital L.P. increased its position in shares of Stoke Therapeutics by 139.3% in the first quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock worth $4,859,000 after acquiring an additional 425,330 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Stoke Therapeutics during the 1st quarter valued at $2,670,000.

Wall Street Analyst Weigh In

STOK has been the subject of several recent analyst reports. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 price objective for the company. Wedbush lifted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Finally, HC Wainwright decreased their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.